PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jgercardJournal of Geriatric CardiologyHomeAboutInstructionsSubmissionEditorial BoardSearch
 
J Geriatr Cardiol. Dec 2012; 9(4): 401–407.
PMCID: PMC3545258
High density lipoproteins and atherosclerosis: emerging aspects
Federica Sala,1 Alberico Luigi Catapano,1,2 and Giuseppe Danilo Norata1,3,4
1Department of Pharmacological Sciences, University of Milan, Via Balzaretti 9, Milan 20133, Italy
2IRCCS Multimedica, Via Milanese 300, Sesto San Giovanni, Milan, Italy
3Centro SISA per lo Studio dell'Aterosclerosi, Ospedale Bassini, Via Gorki 50 Cinisello Balsamo, Italy
4The Blizard Institute, Barts and the London School of Medicine & Dentistry Queen Mary University, Turner Street, London E1 2AD, UK
Correspondence to: Giuseppe Danilo Norata, PhD, Department of Pharmacological Sciences, University of Milan, Italy. Via Balzaretti 9, 20133, Milan, Italy. E-mail: Danilo.Norata/at/unimi.it, Telephone:+39-02-50318313, Fax:+39-02-50318386
Received December 28, 2011; Revised June 4, 2012; Accepted October 22, 2012.
High density lipoproteins (HDL) promote the efflux of excess cholesterol from peripheral tissues to the liver for excretion. This ability is responsible for the most relevant anti-atherogenic effect of HDL. The ability of HDL to promote cholesterol efflux results also in the modulation of a series of responses in the immune cells involved in atherosclerosis, including monocyte-macrophages, B and T lymphocytes. Furthermore, during inflammation, the composition of this class of lipoproteins varies to a large extent, thus promoting the formation of dysfunctional HDL. The aim of this review is to discuss the emerging role of HDL in modulating the activity of immune cells and immune-inflammatory mediators during atherogenesis.
Keywords: High density lipoproteins, Apolipoprotein, Sphingosine-1-phosphate, Immune response
Atherosclerosis and its clinical manifestations are the leading causes of morbidity and mortality in the Western World. For decades, atherosclerosis has been considered only as a disease associated with dyslipidemia.[1]
More recently, both preclinical and clinical research has provided important evidence that inflammation and immune response are integral components of atherogenesis. Therefore, atherosclerosis is now considered a chronic immune-inflammatory disease characterized by the presence of immune cells during all stages of the progression of atherosclerotic plaque.[2]
During the early phase of the disease, an endothelial injury initiates the entire process. According to the “oxidation hypothesis,” endothelial dysfunction causes the retention of low-density lipoproteins (LDL) in the intima where they undergo oxidative modifications.[1] These modified lipids induce the expression of adhesion molecules, chemokines, proinflammatory cytokines, and other mediators of inflammation. Then, leucocytes, penetrated into subendothelial space, actively participate to perpetuate local inflammatory response.
The monocytes-macrophages express scavenger receptors for modified lipoproteins, permitting them to ingest lipid and become foam cells. In addition to monocyte chemoattractant protein-1 (MCP-1), macrophage colony-stimulating factor (M-CSF) contributes to the differentiation of the blood monocyte into the macrophage foam cell.[1]
T cells likewise encounter signals that cause them to elaborate inflammatory cytokines such as interferon and tumor necrosis factor that in turn can stimulate macrophages as well as vascular endothelial cells and smooth muscle cells (SMCs).[2]
As this inflammatory process continues, the activated leukocytes and arterial cells can release fibrogenic mediators, including a variety of peptide growth factors that can promote replication of SMCs and contribute to elaboration by these cells of a dense extracellular matrix, characteristic of the more advanced atherosclerosis lesion.[1]
HDL possess a number of physiological activities. Mature HDL present a hydrophobic core composed of cholesteryl esters and triglycerides with proteins embedded in a lipid monolayer composed mainly of phospholipids and free cholesterol. HDL contain several apolipoproteins including apolipoprotein A-I (apoA-I) and apoA-II, the two main proteins, and a large number of less abundant proteins including apoCs, apoE, apoD, apoJ and some enzymes such as lecithin-cholesterol acyltransferase, serum paraoxonase (PON1) and platelet-activating factor acetylhydrolase (PAF-AH).[3] The most relevant function of HDL is to promote the efflux of excess cholesterol from peripheral tissues to the liver for excretion,[4],[5] a pathway known as reverse cholesterol transport (RCT). The efflux of cholesterol is important for maintaining cellular cholesterol homeostasis. This process is most likely compromised in the atherosclerotic lesion also because the development of atherosclerosis is usually associated with low HDL-cholesterol. Multiple mechanisms for efflux of cell cholesterol exist. Efflux of free cholesterol via aqueous diffusion occurs with all cell types but is inefficient. Efflux of cholesterol is accelerated when scavenger receptor class-B type I (SR-BI) is present in the cell plasma membrane. Both diffusion-mediated and SR-BI-mediated efflux occur to phospholipid-containing acceptors (i.e., HDL and lapidated apolipoproteins). In both cases, the flux of cholesterol is bidirectional, with the direction of net flux dependant on the cholesterol gradient. The adenosine triphosphate binding cassette transporter AI (ABCA1) and GI (ABCG1) mediate efflux of both cellular cholesterol and phospholipid. In contrast to SR-BI-mediated flux, efflux via ABCA1 and ABCG1 are unidirectional, occurring to lipid-poor apolipoproteins.[6] Of note, these transporters are clustered together with many other functional proteins [including B and T cell receptors (BCR and TCR), sphingosine-1-phosphate receptors (S1PR)] in cellular membrane micro-domains called lipid rafts.[7] Lipid rafts are regions of membranes with a distinct, characteristic structural composition and that appear to act as platforms to co-localize proteins involved in intracellular signaling pathways. The organization of membranes into such micro-domains recognizes that, far from being randomly arranged, lipids may actually be highly organized within different parts of the membrane, and that this organization influences the way membrane proteins are distributed. Rafts are particularly rich in sphingolipids and cholesterol, and the side chains of the phospholipids present are usually highly enriched in saturated fatty acids compared with the surrounding non-raft regions of the membrane. Enrichment of phospholipids with saturated fatty acids allows for the close packing of lipids within rafts. As a result of the presence of cholesterol and saturated fatty acids, lipid rafts are more ordered and less fluid than the surrounding membrane. Cytoplasmic proteins that are covalently modified by saturated fatty acids (palmitoyl or myristoyl moieties) and cell surface proteins that are attached via a glycosyl phosphatidyl-inositol anchor are highly concentrated within lipid rafts. Many proteins involved in signal transduction, such as Src family kinases, G proteins, growth factor receptors, mitogen-activated protein kinases (MAPK), and protein kinase C, are predominantly found in lipid rafts, which appear to act as signaling platforms by bringing together (i.e., co-localizing) various signaling components, thus facilitating their interaction.[8]
The integrity of the lipid raft structure is a fundamental requirement for the correct functionality of all the present proteins. Thus, it can be understood why lipid rafts are the key structure responsible for the remarkable ability of HDL to regulate a number of physiological processes, including innate and adaptive immune responses.
In addition, apolipoproteins, lipids and enzymes carried by HDL can also modulate endothelial functions and have antioxidant activities that inhibit the oxidative modification of LDL, thereby reducing the atherogenic potential of these lipoproteins.[9] Of note, HDL is the predominant lipoprotein class in several species (from fish to ape) including those resistant to the development of atherosclerosis or cardiovascular diseases. Furthermore, the main constituent of HDL, apoA-I, is highly conserved throughout evolution,[10] as is the ability of HDL to modulate cholesterol bioavailability at the cellular level.[11] Cholesterol modulation in cells has also been associated with the ability of HDL to modulate hematopoietic stem cell maturation.[7],[11][13] Other players of the immune response are modulated by HDL. HDL induce the expression of pentraxin 3 (PTX3)[14] which is involved in controlling leukocyte recruitment.[15] HDL induce PTX3 mRNA expression and protein release, whereas no effect was observed on CRP and SAP expression. This effect is mainly dependent on the activation of the lysosphingolipid receptor-PI3K/Akt axis and is mimicked by sphingosine-1-phosphate and other S1P mimetics.[14] In vivo, an increased expression of PTX3 mRNA was detected in the aorta of transgenic mice overexpressing human apoA-I, compared to apoA-I knock-out mice and plasma levels of PTX3 are significantly increased in C57BL/6 mice injected with HDL.[14] Of note, PTX3 deficiency is associated with cardiovascular disorders including atherosclerosis.[16],[17] We have demonstrated that PTX3 deficient animals with the apolipoprotein E−/− background, develop larger and more inflamed atherosclerotic lesions compared to control animals.[17]
The aim of this brief review is to discuss the emerging role of HDL in modulating the activity of immune cells and immune-inflammatory mediators during atherogenesis.
In the acute phase response, HDL-cholesterol and apoA-I levels are reduced in humans.[18],[19] The quick change in HDL and apoA-I during acute response is commonly perceived as an adaptation of this system to inflammation. While the inflammatory response represents a host defense to invading pathogens, uncontrolled systemic inflammation can lead to serious complications, such as disseminated intravascular coagulation, tissue damage, and endotoxic shock.[20] For instance, lipopolysaccharides (LPS) are the primary cause of Gram-negative-induced sepsis. LPS, through its interaction with the LPS-binding protein (LBP)-CD14-TLR4 (Toll like receptor 4) complex, activates macrophages, causing a massive release of inflammatory cytokines.[21] LBP binds preferentially to HDL.[22] Of note, intravenous infusion of reconstituted HDL protects mice from the toxic effect of LPS,[23] an effect less evident in rabbits.[24] Furthermore, protection from LPS toxicity was achieved in transgenic mice with a two fold elevation of HDL;[23] this animal model shows more LPS bound to HDL, lower plasma cytokine levels and improved survival rates compared to control mice.
Also in humans, low HDL levels are associated with increased sensitivity toward inflammatory stimuli as reflected by enhanced inflammatory and coagulation responses on endotoxin challenge.[25] Transgenic animals lacking apoA-I, exhibit an increased lipopolysaccharide-driven mortality.[22],[26] Because of the significant protection against LPS-induced damage, reconstituted HDL and apoA-I mimetics represent an interesting approach to improve the control of endotoxemia.[23],[27] Milestones studies pointed out that the capacity of HDL to bind LPS is 10- to 1000-fold above the LPS concentrations reported in studies of septic patients.[28],[29] It is therefore unlikely that the maximal increase in HDL levels achieved (2 to 3-fold) could result in rescue from LPS endotoxemia and lethality only through LPS sequestration and hepatic clearance. This has been widely investigated in the last two decades showing a series of additional HDL effects on the cells and the events involved in the immune-inflammatory response.
Following an infection, circulating HDL, known as “acute-phase HDL” (sometimes regarded also as pro-inflammatory HDL), show altered chemical and physical characteristics. Mediators of inflammation, such as tumor necrosis factor (TNF)-α and interleukin (IL)-6, induce expression of serum amyloid A[30] and group IIA secretory phospholipase A2 (sPLA2-IIA),[31] which dramatically alter HDL apolipoprotein content and levels, respectively. Furthermore, during inflammation, the composition of HDL is modified by the binding of acute phase products, such as serum amyloid A (SAA) and ceruloplasmin.[32] The content of proteins associated with HDL is altered so that PON1 levels decrease, thus reducing the anti-oxidant properties of HDL,[33] while PAF-AH increases leading to an increase of pro-atherogenic lipids.[34],[35] These structural changes in the HDL induce functional lipoprotein alterations that can account, at least in part, for the increased risk of atherosclerosis observed during the acute phase response. For instance, the antioxidant properties of HDL and its function as a cholesterol acceptor are significantly reduced in subjects undergoing an acute phase response.[36][38] During the acute phase, SAA rapidly associates with HDL becoming the main protein,[39],[40] accounting for 17% to 87% of the total apoproteins in acute-phase HDL.
One of the key events in the atherogenic process is the development of foam cells following monocytes-derived macrophage lipid engulfment.[41],[42] Following cholesterol deposition, macrophages activate cholesterol removal mechanisms through the interaction of ABCA1 and ABCG1 and apoA-I or HDL.[43],[44] This interaction negatively modulates macrophage expression of inflammatory mediators, such as MCP-1 and CD11b,[45] and inhibits the lymphocyte proliferative response.[46],[47] Furthermore, macrophages lacking ABCA1 and/or ABCG1 exhibit an increased lipid raft formation.[48] The function of the lipid raft is correlated to its cholesterol content and the removal of cholesterol from these micro-domains can interfere with signaling pathways in immune cells,[49] and with antigen-presenting function.[50] One main function of lipid rafts is the regulation of signaling through the T cell receptors.[51][53] As an example, the localization of major histocompatibility (MHC) class II molecules in lipid rafts[54][56] facilitate the function of antigen-presenting cells and is essential for T cell activation, as this process decreases the amount of antigen necessary for T cell activation.[57],[58] For this reason, cholesterol depletion from lipid rafts can inhibit T cell activation. Both HDL and apoA-I remove cholesterol from lipid rafts via ABCG1, SR-BI and ABCA1, reducing the inflammatory response in macrophages and inhibiting the ability of antigen-presenting cells to stimulate T-lymphocytes.[48],[59]
Dendritic cells (DCs) are immune cells whose main function is to process an antigen, present it on their surface and activate T-cells. DCs are present in atherosclerotic lesions[60] and co-localize with T-cells.[61] DCs produce mediators of the innate immune system and increase the expression of costimulatory molecules, including CD40, CD80 and CD86,[62],[63] which are essential for T-cell responses. ApoA-I inhibits DCs differentiation from monocytes, inhibits the ability of DCs to secrete IL-12 when stimulated with anti-CD40 and interferon γ (IFNγ), and increases the production of two inhibitors of DC differentiation, such as IL-10 and PGE2.[64]
Atherosclerotic lesions also contain cells of the adaptive immune system, in particular T cell subsets known to modulate inflammatory process in atherogenesis. BCR and TCR are localized in lipid rafts. In resting cells, BCR and TCR are excluded from lipid rafts. Upon activation, these receptors associate with membrane micro-domains, resulting in a spatial organization of receptor signaling.[65] The association of BCR and TCR with lipid rafts is dependent on membrane cholesterol content and changes in lipid raft composition and structure induced by HDL or apoA-I can affect receptor activities.[66],[67] Both B and T cells egression from lymph nodes is also affected by lysosphingolipids, in particular S1P, a component of HDL.[68][70] S1P carried by HDL positively correlates with HDL-cholesterol, apoA-I, and apoA-II levels. Furthermore, S1P is enriched in small dense subclass 3 of HDL (HDL3).[71] Modulation of S1P1 receptors by a synthetic S1P analogue, FTY720, in LDL-R knockout mice resulted in a marked decrease of peripheral blood lymphocytes, thus preventing their recruitment into sites of inflammation.[72],[73] Finally, FTY720 reduces the delivery of scavenged lipoprotein cholesterol to the endoplasmic reticulum and facilitates its release to physiological extracellular acceptors, resulting in decreased cholesterol toxicity in macrophages.[74] S1P1 is the main S1P receptor involved in the egress of T cells from lymphoid organs (Table 1).[58],[59] In transgenic mice, S1P1 inhibited the differentiation of regulatory T cells (Tregs) while promoting the development of T helper type 1 (Th1) cells in a reciprocal manner.[70] We recently showed, in humans, an inverse relation between a HDL and CD3+ CD4+CD25high CD127low Treg cell levels, while no correlation was found between Tregs and LDL cholesterol, total cholesterol or triglyceride levels.[75] In animal models, other mechanisms by which HDL can modulate Treg have been proposed. ApoA-I administration reduces inflammation in LDL receptor−/−, apoA-I−/− mice by decreasing the numbers of lymph node immune cells, by increasing Tregs and decreasing the percentage of effector memory T cells.[76] All these data suggest that some of the effects of HDL on atherosclerosis may result from the modulation of molecules and cells that act as sensors of the immune-inflammatory balance during atherogenesis.
Table 1.
Table 1.
Immune cells and atherosclerosis: effects of HDL and its components.
HDL acts as reservoir for a number of biologically active substances that may impact the immune system during atherogenesis. Of note, modifications in the lipid and lipoprotein profiles are highly correlated to lymphocyte T effecttor memory cells and the risk of cardiovascular events.[73] Therefore, the ability of HDL to promote cholesterol efflux results in the modulation of a series of responses in the immune cells involved in atherosclerosis, including monocyte-macrophages, B and T lymphocytes. Since the HDL composition varies to a large extent during inflammation, the understanding of how these interactions take place and how biologically active substances can be delivered to relevant targets during atherogenesis is of great interest. Drugs targeting HDL levels and activity represent one of the emerging frontiers in lipidology and pharmacology. Whether these drugs impact the immune-inflammatory response in atherosclerosis will be extensively investigated in subsequent years.
1. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell. 2001;104:503–516. [PubMed]
2. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12:204–212. [PubMed]
3. Navab M, Ananthramaiah GM, Reddy ST, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res. 2004;45:993–1007. [PubMed]
4. von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:13–27. Role of cholesterol efflux and reverse cholesterol transport. [PubMed]
5. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127–135. [PMC free article] [PubMed]
6. Duong M, Collins HL, Jin W, et al. Relative contributions of ABCA1 and SR-BI to cholesterol efflux to serum from fibroblasts and macrophages. Arterioscler Thromb Vasc Biol. 2006;26:541–547. [PubMed]
7. Norata GD, Pirillo A, Ammirati E, et al. Emerging role of high density lipoproteins as a player in the immune system. Atherosclerosis. 2012;220:11–21. [PubMed]
8. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000;1:31–39. [PubMed]
9. Calabresi L, Gomaraschi M, Franceschini G. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol. 2003;23:1724–1731. [PubMed]
10. Collet X, Marcel YL, Tremblay N, et al. Evolution of mammalian apolipoprotein A-I and conservation of antigenicity: correlation with primary and secondary structure. J Lipid Res. 1997;38:634–644. [PubMed]
11. Hansson GK, Bjorkholm M. Medicine. Tackling two diseases with HDL. Science. 2010;328:1641–1642. [PubMed]
12. Yvan-Charvet L, Pagler T, Gautier EL, et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science. 2010;328:1689–1693. [PMC free article] [PubMed]
13. Norata GD, Pirillo A, Catapano AL. HDLs, immunity, and atherosclerosis. Curr Opin Lipidol. 2011;22:410–416. [PubMed]
14. Norata GD, Marchesi P, Pirillo A, et al. Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol. 2008;28:925–931. [PubMed]
15. Deban L, Russo RC, Sironi M, et al. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol. 2010;11:328–334. [PubMed]
16. Norata GD, Garlanda C, Catapano AL. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med. 2010;20:35–40. [PubMed]
17. Norata GD, Marchesi P, Pulakazhi Venu VK, et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation. 2009;120:699–708. [PubMed]
18. Khovidhunkit W, Kim MS, Memon RA, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. 2004;45:1169–1196. [PubMed]
19. Coetzee GA, Strachan AF, van der Westhuyzen DR, et al. Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J Biol Chem. 1986;261:9644–9651. [PubMed]
20. Han J, Ulevitch RJ. Limiting inflammatory responses during activation of innate immunity. Nat Immunol. 2005;6:1198–1205. [PubMed]
21. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 2008;8:776–787. [PMC free article] [PubMed]
22. Wurfel MM, Kunitake ST, Lichenstein H, et al. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med. 1994;180:1025–1035. [PMC free article] [PubMed]
23. Levine DM, Parker TS, Donnelly TM, et al. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci U S A. 1993;90:12040–12044. [PubMed]
24. Hubsch AP, Powell FS, Lerch PG, et al. A reconstituted, apolipoprotein A-I containing lipoprotein reduces tumor necrosis factor release and attenuates shock in endotoxemic rabbits. Circ Shock. 1993;40:14–23. [PubMed]
25. Birjmohun RS, van Leuven SI, Levels JH, et al. High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans. Arterioscler Thromb Vasc Biol. 2007;27:1153–1158. [PubMed]
26. Cai L, Ji A, de Beer FC, et al. SR-BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance. J Clin Invest. 2008;118:364–375. [PMC free article] [PubMed]
27. Gupta H, Dai L, Datta G, et al. Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide. Circ Res. 2005;97:236–243. [PubMed]
28. Tobias PS, McAdam KP, Soldau K, et al. Control of lipopolysaccharide-high-density lipoprotein interactions by an acute-phase reactant in human serum. Infect Immun. 1985;50:73–76. [PMC free article] [PubMed]
29. Munford RS, Andersen JM, Dietschy JM. Sites of tissue binding and uptake in vivo of bacterial lipopolysaccharide-high density lipoprotein complexes: studies in the rat and squirrel monkey. J Clin Invest. 1981;68:1503–1513. [PMC free article] [PubMed]
30. Cabana VG, Siegel JN, Sabesin SM. Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J Lipid Res. 1989;30:39–49. [PubMed]
31. Menschikowski M, Hagelgans A, Siegert G. Secretory phospholipase A2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases? Prostaglandins Other Lipid Mediat. 2006;79:1–33. [PubMed]
32. Van Lenten BJ, Navab M, Shih D, et al. The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc Med. 2001;11:155–161. [PubMed]
33. Feingold KR, Memon RA, Moser AH, et al. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis. 1998;139:307–315. [PubMed]
34. Cao Y, Stafforini DM, Zimmerman GA, et al. Expression of plasma platelet-activating factor acetylhydrolase is transcriptionally regulated by mediators of inflammation. J Biol Chem. 1998;273:4012–4020. [PubMed]
35. Memon RA, Fuller J, Moser AH, et al. In vivo regulation of plasma platelet-activating factor acetylhydrolase during the acute phase response. Am J Physiol. 1999;277:R94–R103. [PubMed]
36. Navab M, Anantharamaiah GM, Reddy ST, et al. HDL as a biomarker, potential therapeutic target, and therapy. Diabetes. 2009;58:2711–2717. [PMC free article] [PubMed]
37. Banka CL, Yuan T, de Beer MC, et al. Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. J Lipid Res. 1995;36:1058–1065. [PubMed]
38. McGillicuddy FC, de la Llera Moya M, Hinkle CC, et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation. 2009;119:1135–1145. [PubMed]
39. Clifton PM, Mackinnon AM, Barter PJ. Effects of serum amyloid A protein (SAA) on composition, size, and density of high density lipoproteins in subjects with myocardial infarction. J Lipid Res. 1985;26:1389–1398. [PubMed]
40. Van Lenten BJ, Hama SY, de Beer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995;96:2758–2767. [PMC free article] [PubMed]
41. Lusis AJ. Atherosclerosis. Nature. 2000;407:233–241. [PMC free article] [PubMed]
42. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340:115–126. [PubMed]
43. Oram JF. ATP-binding cassette transporter A1 and cholesterol trafficking. Curr Opin Lipidol. 2002;13:373–381. [PubMed]
44. Wang X, Collins HL, Ranalletta M, et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest. 2007;117:2216–2224. [PMC free article] [PubMed]
45. Moudry R, Spycher MO, Doran JE. Reconstituted high density lipoprotein modulates adherence of polymorphonuclear leukocytes to human endothelial cells. Shock. 1997;7:175–181. [PubMed]
46. Bensinger SJ, Bradley MN, Joseph SB, et al. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell. 2008;134:97–111. [PMC free article] [PubMed]
47. Wilhelm AJ, Zabalawi M, Grayson JM, et al. Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunity. Arterioscler Thromb Vasc Biol. 2009;29:843–849. [PMC free article] [PubMed]
48. Landry YD, Denis M, Nandi S, et al. ATP-binding cassette transporter A1 expression disrupts raft membrane microdomains through its ATPase-related functions. J Biol Chem. 2006;281:36091–36101. [PubMed]
49. Kabouridis PS, Janzen J, Magee AL, et al. Cholesterol depletion disrupts lipid rafts and modulates the activity of multiple signaling pathways in T lymphocytes. Eur J Immunol. 2000;30:954–963. [PubMed]
50. Anderson HA, Hiltbold EM, Roche PA. Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation. Nat Immunol. 2000;1:156–162. [PubMed]
51. Jury EC, Flores-Borja F, Kabouridis PS. Lipid rafts in T cell signalling and disease. Semin Cell Dev Biol. 2007;18:608–615. [PMC free article] [PubMed]
52. Kabouridis PS. Lipid rafts in T cell receptor signalling. Mol Membr Biol. 2006;23:49–57. [PMC free article] [PubMed]
53. Zeyda M, Stulnig TM. Lipid Rafts & Co.: an integrated model of membrane organization in T cell activation. Prog Lipid Res. 2006;45:187–202. [PubMed]
54. Hiltbold EM, Poloso NJ, Roche PA. MHC class II-peptide complexes and APC lipid rafts accumulate at the immunological synapse. J Immunol. 2003;170:1329–1338. [PubMed]
55. Poloso NJ, Roche PA. Association of MHC class II-peptide complexes with plasma membrane lipid microdomains. Curr Opin Immunol. 2004;16:103–107. [PubMed]
56. Setterblad N, Roucard C, Bocaccio C, et al. Composition of MHC class II-enriched lipid microdomains is modified during maturation of primary dendritic cells. J Leukoc Biol. 2003;74:40–48. [PubMed]
57. Eren E, Yates J, Cwynarski K, et al. Location of major histocompatibility complex class II molecules in rafts on dendritic cells enhances the efficiency of T-cell activation and proliferation. Scand J Immunol. 2006;63:7–16. [PubMed]
58. Zilber MT, Setterblad N, Vasselon T, et al. MHC class II/CD38/CD9: a lipid-raft-dependent signaling complex in human monocytes. Blood. 2005;106:3074–3081. [PubMed]
59. Murphy AJ, Woollard KJ, Hoang A, et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol. 2008;28:2071–2077. [PubMed]
60. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:1876–1890. [PubMed]
61. Bobryshev YV, Lord RS. Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immune-inflammatory reactions. Cardiovasc Res. 1998;37:799–810. [PubMed]
62. Niessner A, Weyand CM. Dendritic cells in atherosclerotic disease. Clin Immunol. 134:25–32. [PMC free article] [PubMed]
63. Dopheide JF, Sester U, Schlitt A, et al. Monocyte-derived dendritic cells of patients with coronary artery disease show an increased expression of costimulatory molecules CD40, CD80 and CD86 in vitro. Coron Artery Dis. 2007;18:523–531. [PubMed]
64. Kim KD, Lim HY, Lee HG, et al. Apolipoprotein A-I induces IL-10 and PGE2 production in human monocytes and inhibits dendritic cell differentiation and maturation. Biochem Biophys Res Commun. 2005;338:1126–1136. [PubMed]
65. Dykstra M, Cherukuri A, Sohn HW, et al. Location is everything: lipid rafts and immune cell signaling. Annu Rev Immunol. 2003;21:457–481. [PubMed]
66. Gupta N, DeFranco AL. Lipid rafts and B cell signaling. Semin Cell Dev Biol. 2007;18:616–626. [PMC free article] [PubMed]
67. Kabouridis PS, Jury EC. Lipid rafts and T-lymphocyte function: implications for autoimmunity. FEBS Lett. 2008;582:3711–3718. [PMC free article] [PubMed]
68. Pappu R, Schwab SR, Cornelissen I, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science. 2007;316:295–298. [PubMed]
69. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002;296:346–349. [PubMed]
70. Liu G, Yang K, Burns S, et al. The S1P(1)-mTOR axis directs the reciprocal differentiation of T(H)1 and T(reg) cells. Nat Immunol. 2010;11:1047–1056. [PMC free article] [PubMed]
71. Scanu AM, Edelstein C. HDL: bridging past and present with a look at the future. Faseb J. 2008;22:4044–4054. [PubMed]
72. Nofer JR, Bot M, Brodde M, et al. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. 2007;115:501–508. [PubMed]
73. Keul P, Tolle M, Lucke S, et al. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2007;27:607–613. [PubMed]
74. Blom T, Back N, Mutka AL, et al. FTY720 stimulates 27-hydroxycholesterol production and confers atheroprotective effects in human primary macrophages. Circ Res. 2010;106:720–729. [PMC free article] [PubMed]
75. Ammirati E, Cianflone D, Banfi M, et al. Circulating CD4+ CD25hiCD127lo regulatory T-Cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30:1832–1841. [PubMed]
76. Wilhelm AJ, Zabalawi M, Owen JS, et al. Apolipoprotein A-I modulates regulatory T cells in autoimmune LDLr−/−, ApoA- I−/− mice. J Biol Chem. 2010;285:36158–36169. [PubMed]
Articles from Journal of Geriatric Cardiology : JGC are provided here courtesy of
Institute of Geriatric Cardiology, Chinese PLA General Hospital